TY - JOUR
T1 - Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes
AU - Liu, Kui
AU - Liang, Chaoying
AU - Liang, Zhiyan
AU - Tus, Katalin
AU - Wakeland, Edward K.
PY - 2005/2/1
Y1 - 2005/2/1
N2 - The Sle1ab genomic interval on murine chromosome 1 mediates the loss of immune tolerance to chromatin resulting in antinuclear Abs (ANA) production in the lupus-prone NZM2410 mouse. Global gene expression analysis was used to identify the molecular pathways that are dysregulated at the initiation of B lymphocyte autoimmunity in B6.Sle1ab mice. This analysis identified that STAT3 and ras-ERK signaling pathways are aberrantly activated in Sle1ab B lymphocytes, consistent with increased production of IL-6 by splenic B lymphocytes and monocytes in B6.Sle1ab mice. In vitro treatment of splenic mononuclear cells isolated from ANA-positive Sle1ab mice with anti-IL-6 Ab or AG490, an inhibitor of STAT3 signaling pathway, suppressed ANA production in short-term culture, indicating that this pathway was essential to the production of autoantibodies. In vivo treatment of ANA-positive B6.Sle1ab mice with the ras pathway inhibitor, perillyl alcohol, suppressed the increase of ANA. These findings identify IL-6 as a early key cytokine in Sle1ab-mediated disease development and indicate that the STAT3 and res-ERK signaling pathways are potential therapeutic targets for treating systemic lupus erythematosus.
AB - The Sle1ab genomic interval on murine chromosome 1 mediates the loss of immune tolerance to chromatin resulting in antinuclear Abs (ANA) production in the lupus-prone NZM2410 mouse. Global gene expression analysis was used to identify the molecular pathways that are dysregulated at the initiation of B lymphocyte autoimmunity in B6.Sle1ab mice. This analysis identified that STAT3 and ras-ERK signaling pathways are aberrantly activated in Sle1ab B lymphocytes, consistent with increased production of IL-6 by splenic B lymphocytes and monocytes in B6.Sle1ab mice. In vitro treatment of splenic mononuclear cells isolated from ANA-positive Sle1ab mice with anti-IL-6 Ab or AG490, an inhibitor of STAT3 signaling pathway, suppressed ANA production in short-term culture, indicating that this pathway was essential to the production of autoantibodies. In vivo treatment of ANA-positive B6.Sle1ab mice with the ras pathway inhibitor, perillyl alcohol, suppressed the increase of ANA. These findings identify IL-6 as a early key cytokine in Sle1ab-mediated disease development and indicate that the STAT3 and res-ERK signaling pathways are potential therapeutic targets for treating systemic lupus erythematosus.
UR - http://www.scopus.com/inward/record.url?scp=12444315948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12444315948&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.174.3.1630
DO - 10.4049/jimmunol.174.3.1630
M3 - Article
C2 - 15661926
AN - SCOPUS:12444315948
SN - 0022-1767
VL - 174
SP - 1630
EP - 1637
JO - Journal of Immunology
JF - Journal of Immunology
IS - 3
ER -